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Abstract
Naturally occurring polysaccharides and/or their chemically modified derivatives have 
been widely investigated in relation to their use as components of controlled release sys-
tems for drug delivery. The aforementioned is due, in part, to their distinct properties 
such as abundant availability and biocompatibility as well as environmental and eco-
nomic advantages. Chitosan (CS) and xanthan gum (XG) based matrices have received 
growing scientific/pharmaceutical interest as oral controlled release drug carriers. 
Herein, recent advances spanning the last two decades in CS-XG based drug delivery 
systems are reviewed with the emphasis being on oral tablet formulations, due to their 
versatility as pharmaceutical dosage forms. The mechanism of interaction between CS 
and XG, by means of computational and experimental approaches, is scrutinized. Results 
obtained from the literature establish the possibility of fabricating a controlled release 
drug delivery system based on CS and XG matrices. This can be achieved by monitor-
ing and manipulating the physiochemical properties of the two polymers as well as the 
experimental variables affecting their drug retardation efficiency, without the need to 
employ special equipment or sophisticated experimental techniques/methodologies.
Keywords: drug delivery, controlled release, polymeric matrices, natural 
polysaccharides, xanthan gum, chitosan, polyelectrolyte complexes, molecular 
dynamics simulation
1. Introduction
The ultimate goal in drug design and development is to optimize a carrier that ensures the 
delivery of the active pharmaceutical ingredient(s) (APIs) to the systemic circulation in a safe 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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and stable manner [1]. Patient compliance is a key aspect to consider when designing a new 
pharmaceutical dosage form [2]. Therefore, the way the drug will be introduced to the body 
should be optimized to ensure the availability of the drug at its site of action, at levels within 
the range of its therapeutic window (Figure 1).
Despite emerging advances in drug delivery, the oral route remains the predominant route 
of drug administration. It is the simplest route, non-invasive and provides ~200 m2 of read-
ily available surface area for drug absorption [3]. Conventional oral dosage forms usually 
release drugs immediately in the body, via first order release kinetics for both absorption 
and elimination processes [4]. Since the efficacy of the administered drug is limited to its 
residence time in plasma, frequent administration is required for APIs which exhibit a short 
biological half-life. As a result, low patient compliance and high fluctuation of drug levels in 
plasma is expected [5, 6]. In order to counter the foregoing drawbacks of conventional dos-
age forms, a new term in drug delivery was introduced; modified release dosage forms [7].
The United States Pharmacopeia defines modified release tablets as “coated or uncoated tab-
lets that contain special excipients or are prepared by special procedures, or both, designed to 
modify the rate, the place or the time at which the active substance(s) are released”. Modified 
release delivery systems can be divided into delayed release systems and prolonged/extended 
release systems. Extended release delivery systems can further be subdivided into sustained 
and controlled release delivery systems, which differ in the rate at which they deliver APIs to 
the human blood circulation. Sustained release formulations function by continuously releas-
ing APIs for a prolonged period of time. On the other hand, controlled release (CR) delivery 
systems do not only retard the release of the drug, but they deliver the drug to the body at a 
predetermined release rate or location [8]. Consequently, constant drug levels can be achieved 
(Figure 2).
Figure 1. Plasma levels and therapeutic range of a drug following an oral administration of a single dose. MTC: minimum 
toxic concentration, and MEC: minimum effective concentration.
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2. Controlled drug delivery
CR systems are composed of inactive pharmaceutical ingredient(s) that entrap the API(s) and 
release it/them at a time different from the immediate release form [4]. Researchers in the field 
of drug delivery have, and are currently still trying to acquire a better understanding of CR by 
attempting to integrate pharmaceutical technology with the relevant pharmacokinetic param-
eters associated with different drugs [9]. The rational underpinning controlled drug release 
includes, but are not limited to: masking the undesired side effects of drugs, attaining a con-
stant drug release profile with minimal drug level fluctuations, and enhancing patient con-
venience by reducing administration frequency [10]. CR dosage forms are not only capable 
of extending the time over which drugs are released and providing constant drug levels but 
also with the potential of protecting therapeutic biomolecules such as peptides and proteins 
from enzymatic degradation in the gastrointestinal tract (GIT) [11]. CR systems can also be 
formulated to target the delivery of APIs to the  desired site of action [12, 13].
Aside from the substantial need for CR formulations in drug delivery and the potential 
advantages they offer, the reproducibility and cost of equipment and techniques needed for 
the preparation of CR dosage forms on a large scale present a major obstacle towards the 
Figure 2. Comparison of plasma concentration-time profiles of drug release following multiple dosing from: (a) 
conventional, and (b) controlled-release dosage forms.
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widespread production of CR delivery systems in pharmaceutical manufacturing. Figure 3 
summarizes the key factors which require to be taken into account when optimizing a new 
CR dosage form.
2.1. Design of CR systems
2.1.1. APIs
There are several criteria and properties that should be taken into consideration in the pro-
posed use of an API when designing a controlled release formulation [14, 15].
• The elimination half-life of the drug should be short. Drugs with long half-lives, greater 
than 8 h, provide a sustained release profile without the need to be formulated in a con-
trolled release system.
• Drugs with a wide therapeutic window are better candidates since higher doses need to be 
incorporated in CR formulations and dose dumping could occur.
• The absorption rate of a candidate drug should be high to make sure that the release of 
drug from the CR delivery system is the rate determining step, not the absorption rate.
• Drugs which exhibit high protein binding are retained in the plasma for a long time; thus, 
they do not require a CR delivery system.
• Drugs that undergo extensive first pass metabolism are poor candidates for CR, since re-
leasing the drug at lower rates will decrease its bioavailability. APIs with a bioavailability 
index higher than 75% are preferable.
Figure 3. Key factors to be considered when developing a new dosage form in the pharmaceutical industry.
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2.1.2. Carriers and mechanism of drug release
Controlled drug release can be achieved by utilizing special techniques and devices. As the 
release of a drug from the delivery system is the rate limiting step in controlled release formu-
lations, CR systems are classified according to the mechanism involved in drug release [3, 16]. 
Figure 4. Classification of controlled release drug delivery systems combined with the main mechanisms involved in 
drug release and examples of inactive ingredients used to achieve CR.
Model Equation Mechanism of release
Zero order  Q 
t
  =  Q 0 +  K 0  t Release is independent of drug concentration within the matrix or device
First order  Ln  Q 
t
  = Ln  Q 0 + Kt Release is dependent on drug concentration within the matrix or device
Higuchi  Q 
t
  =  K 
H
   t 1/2 Drug released via diffusion through an insoluble polymeric matrix
Hixon-Crowel  Q 0 1/3 −  Q t 1/3  =  K HC  t Drug release is dependent on drug dissolution rate in the media
Korsmeyer-Peppas  Q 
t
  / Q = K  t n This model is used when several mechanisms are involved in drug 
release from the system
*Where Q0 is the initial amount of drug in the dissolution media, Qt is the fraction released at time t, K is the rate release constant, and n is the release exponent.
Table 1. Mathematical models of drug release kinetics from CR formulations*.
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In some preparations, more than one mechanism can be involved in the release of the API(s) 
from the CR systems (Figure 4).
2.1.3. In-vitro drug release kinetics
Since the objective of utilizing CR systems is to deliver a drug, or drugs, over a known time 
interval, several mathematical models (Table 1) have been suggested to describe drug release 
from the systems as a function of time.
3. Natural polysaccharides
Polymers are the most used materials to control the release of APIs. They can be classified as 
synthetic (silicons, polyesters and cellulose derivatives) and natural polymers (proteins and 
polysaccharides). Many naturally occurring polymers are inert, biodegradable, and cost-effec-
tive in relation to their industrial use [17]. In addition, their chemical structure can usually be 
easily modified to achieve the desired properties for a specific purpose [18]. Hence, the utiliza-
tion of natural polymers as components of drug vehicles is gaining extensive attention [3]. The 
most used polymers are saccharides (carrageenan, cellulose) or proteins (collagen, gelatin) [19].
Natural polysaccharides are hydrophilic polymers consisting of repeating monosaccharide 
units linked via glycosidic bonds [20]. They are obtained from various sources, mainly vegetal 
(cellulose, starch), microbes (xanthan gum, dextran), crustaceans (chitin) and algae (alginate, 
carrageenan) [21, 22]. Depending on the identity of the constituent monomer(s), polysaccha-
rides can be divided into homo-polysaccharides which are composed of the same repeating 
unit, such as cellulose, or hetero-polysaccharides which are built up from different saccharide 
units e.g., CS and XG [23, 24]. They can also be classified according to their ionic charge: non-
polyelectrolyte (starch, cellulose), and polyelectrolyte polysaccharides. Polyelectrolytes are 
further sub-divided into negatively charged polymers; such as alginate and XG, or positively 
charged polymers, which are few in number, such as CS [25, 26].
The unique physicochemical characteristics of each polysaccharide are related to the type of 
monosaccharide building unit, position of the glycosidic bond, chain substitution and the over-
all molecular weight [25, 27]. Due to the presence of various functional groups attached to the 
polymer backbone (carboxyl ─COOH, amine ─NH2 and hydroxyl groups ─OH), polysaccha-
rides have the ability to form non-covalent bonds with a wide range of synthetic and biological 
molecules [28, 29]. Moreover, they can attach to body tissues and mucus layers and sustain the 
release of encapsulated active ingredients [13]. The aforementioned properties have attracted 
attention towards the usage of polysaccharides in major industries including food, agronomy, 
cosmetics, biochemical engineering and pharmaceutical manufacturing [30, 31].
3.1. Chitosan (CS)
CS is a linear polysaccharide produced by the N-deacetylation of chitin [32]. Chitin is found 
mainly in the exoskeleton of marine crustaceans as well as insects and fungi [33]. Glucosamine 
and N-acetyl glucosamine are the building units of CS. They are linked via β(1-4)glycosidic 
bonds (Figure 5a). The degree of acetylation and distribution of acetyl groups along the polymer 
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chain (either block or random distribution) are dependent on the duration of the deacetylation 
process and preparation method for CS [34, 35]. Following deacetylation of chitin, CS is (unlike 
chitin) soluble in acidic media. Moreover, the presence of primary amine groups leads to the 
unique properties of CS over all other natural polysaccharides [36]. It is the only saccharide 
possessing a high density positive net charge, which allows it to interact with a wide range of 
anionic polymers and biological molecules [32]. In addition, CS shows high mucoadhesion in 
the GIT which increases the residence time and enhances the permeation of active molecules 
[30]. Hence, CS is used commonly in the food industry, for pharmaceutical drug delivery and 
tissue engineering [37, 38].
3.2. Xanthan gum (XG)
XG is a branched, hetero-polysaccharide produced via microbial fermentation of the microor-
ganism Xanthomonas campestris [39]. The primary unit of XG (Figure 5b) consists of a cellulosic 
backbone composed of two d-glucose units (1-4) β-linked to a side-chain of d-mannose and 
d-glucuronic acid units at a ratio of 2:1, respectively [40]. d-Mannose, which is connected to 
the main backbone, is attached to an acetyl group at O6, while approximately half of the ter-
minal d-mannose forms a pyruvic acid group between carbons C4 and C6. This side-chain is 
found at the O3 atom of each alternate glucose unit on the backbone. Due to the presence of 
carboxylic groups in its structure, XG exhibits a net negative charge and can form complexes 
Figure 5. Schematic chemical structures of the building units of: (a) CS and (b) XG.
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with cationic polymers [41]. In the last decade, the demand for XG, in industry, has been 
increasing at about 5–10% per annum [42]. It is used in a broad variety of industries, including 
cosmetics, agriculture, food, textiles and oil [43, 44]. This is due to its safety (non-toxic), desir-
able rheological properties, high stability over a wide range of pH and temperature, together 
with its high resistance against enzymatic degradation [45, 46].
4. CS and XG matrices as controlled release drug delivery systems
4.1. Advances and applications
Matrix systems, based on polyelectrolyte polysaccharides, used to retard the release of APIs 
have been reported in the literature and some of them have been commercialized [29, 47]. 
The long term instability of their corresponding preparations due to the existence of charged 
groups limits their application in pharmaceutical manufacturing [48]. Introducing a cross-
linker, such as tripolyphosphate or glutaraldehyde, to neutralize the polymeric matrix is a 
necessary approach to confront such a shortcoming. Though, substituting the cross-linker 
with an oppositely charged copolymer aids and abbets the synergistic effect of drug release 
retardation. XG proved to be a potential CR drug carrier. In aqueous solutions, XG shows 
high viscosity and water uptake capacity encapsulating the drug inside a thick gel-like layer 
which hinders the release of the incorporated drug. XG has been used alone and with other 
polymers such as HPMC, karaya gum, guar gum, and polyvinylpyrrolidone (PVP), or ethyl 
cellulose [49–53]. Formulated matrices were able to sustain the release of caffeine, azithromy-
cin, ibuprofen and propranolol HCl. XG demonstrates a high capability of generating a near 
zero drug release profile.
Being the only known positively charged natural polymer in aqueous solutions, CS has been 
extensively investigated as a potential drug vehicle. CS has the ability to preserve the stability 
of active biomolecules, namely insulin, and enhance their absorption from the GIT [54–56]. 
CS was mixed with various polymers with the aim of modifying the release of active ingredi-
ents, protect genes and therapeutic peptides in the GIT and improve their permeation across 
the intestinal epithelium and to immobilize antibodies [57–59]. Alginate, carrageenan, pectin, 
hyaluronic acid and XG are amongst the many natural polymers to be used with CS [47, 60, 61].
The combination of CS and XG was first used in the form of a polyelectrolyte complex 
(PEC) hydrogel [62]. The hydrogels formed displayed pH dependent swelling behavior and 
addressed the possibility of developing a gastrointestinal drug delivery system. PECs are 
formed due to the attractive ionic forces between the positively charged amino groups in 
CS and the negatively charged carboxyl groups in XG [63]. Therefore, features of the PECs 
produced can be controlled by manipulating the physicochemical properties of each polymer 
[64]. Molecular weight, degree of acetylation (DA) of CS, and pyruvic acid content in XG 
are amongst the most crucial factors to be addressed [47, 65, 66]. Complexation conditions 
(including concentration of each polymer, mixing ratios, and pH) have a significant influence 
on the behavior and stability of the resulting PEC [67]. The combination of CS and XG has 
been extensively studied as a platform for CR drug delivery, resulting in many patents and 
the publication of research articles.
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4.1.1. Patents on CS-XG based controlled release drug delivery system
CS-XG hydrogels have been studied in order to immobilize biological materials. This is due to 
their insolubility and high stability in acidic medium allowing the system to preserve biological 
activity and release the materials at neutral pH. CS-XG hydrogels served as a promising can-
didate for sustained release dosage forms [68]. CS-XG hydrogels were capable of stabilizing 
and controlling the release of highly sensitive active ingredients such as vitamins, amino acids, 
nucleic acids and polypeptides when applied topically or orally as dietary supplements [69]. 
Moreover, the prepared hydrogels were shown to play a role in regulating the dissolution rate of 
poorly water-soluble drugs as disclosed by the patent WO 2002003962 where fenofibrate, urso-
deoxycholic acid, nifedipine and indomethacin were used as models of poorly water-soluble 
APIs [70].
Tablets comprising CS and XG as a hydrophilic matrix for oral controlled release were first 
presented by Badwan et al. [71]. A wide range of basic drugs were tested (e.g. ambroxol, 
salbutamol, metoclopramide, anti-infective, non-steroidal and anti-inflammatory agents 
(NSAIDs)). Tablets formulated using CS and XG have been used to deliver basic APIs in a 
controlled release pattern. The drug to polymer ratio used was 1:3, respectively and the pre-
ferred XG to CS ratio was 1:1. When the system was studied in-vivo on human volunteers, it 
produced constant serum levels of ambroxol over a period of 24 h. This study paved the way 
for further research on approaches and mechanisms involving tablet formulations based on 
the foregoing combination. A tablet dosage form based on CS-XG for the treatment of hyper-
cholesterolemia was prepared [72]. A combination of lycopene and Monascus purpureus were 
used as active ingredients. When testing the preparation on human volunteers, a significant 
decrease in the plasma levels of cholesterol, LDL and triglycerides was reported. Moreover, 
HDL values were reported to be increased.
4.1.2. Research articles on CS-XG based controlled release drug delivery system
The applicability of CS-XG combinations to a wide range of dosage forms with different 
routes of administration has been investigated. Examples of the preparations reported in the 
literature together with a brief description of preparation methods, application and examples 
of incorporated APIs are summarized in Table 2.
4.2. Ionic interaction between XG and CS
In spite of the significant amount of research work conducted on XG and CS based matrices, 
a lack of understanding of the nature of the interaction between the two polymers and their 
behavior at the molecular level still exists. It was suggested that physico-chemical conditions 
in the stomach are an ideal environment for the formation of insoluble gels between the two 
polymers, which retards the release of APIs resulting in a sustained drug release profile [87]. 
Moreover, in vitro residence time evaluation on porcine mucin and in vivo studies using 
sheep models have addressed the bioadhesive nature of CS-XG matrices [88].
In order to acquire an understanding of the interaction between XG and CS and factors gov-
erning it, a molecular dynamics simulation (MDs) study was conducted by Dadou et al. [89]. 
The contribution of the DA of CS and protonation was evaluated. The resulting trajectories 
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and binding free energy calculations revealed that electrostatic forces (polar interactions, ∆E
ele
) 
are the driving force for the interaction, and that the interaction occurs regardless of the DA 
and state of protonation of CS (free energy values are negative for all complexes). Protonation 
of CS molecules increases their penetration between the branched chains of XG and produces 
more stable complexes with lower free binding energy (Table 3). Intermolecular interactions 
(Van der Waals) showed a positive contribution to the formation of CS-XG PECs. This can be 
explained by the presence of a large number of hydroxyl groups along the chains of the poly-
mers which can induce an instantaneous dipole attraction with the surrounding atoms. High 
positive solvation free energy (∆Gsolv) values justify the resultant insoluble PECs upon com-plexation between CS and XG in the laboratory. ∆Gsolv increases with protonation, reaching a maximum value when CS is fully protonated, indicating a higher extent of interaction with XG.
4.2.1. Mixing ratio
Since the interaction between CS and XG is electrostatically driven, the properties of the resul-
tant PECs can be modified by controlling the net charge density. This can be achieved either 
by altering the mixing ratios or the initial concentrations of the polymeric solutions. Films of 
CS and XG were prepared and examined by scanning electron microscope (SEM) for addi-
tional information relating to the behavior and the interaction between the two polymers in 
Dosage form Preparation method Application Incorporated ingredient
Hydrogels Solution mixing under heat Drug delivery, tissue 
engineering, immobilization of 
biological active materials
Probiotics [73], enzymes [64]
Films Solution casting Drug delivery, tissue 
engineering, food industry
Wound healing [74], 
amoxicillin [75], scaffolds 
[76]
Capsules Complex coacervation, 
encapsulation of physically 
mixed powder
Drug delivery Theophylline [77], 
ciprofloxacin HCl [78]
Beads Extrusion-dripping technique, 
complex coacervation 
mechanism
Drug delivery, immobilization 
of biological active materials
Probiotics [79], glipizide 
[80], antibodies [59]
Microspheres Spray drying, ionotropic 
gelation method
Drug delivery Meclizine HCl [81]
Micro-emulsions Homogenization with oil 
phase
Drug delivery Progesterone [82]
Liposomes 
(chitosomes)
Thin film hydration method, 
spray drying
Drug delivery Rifampicin [83]
Cryogel Freeze-drying Immobilization of biological 
active materials
Enzymes [84]
Tablets Direct compression, 
granulation, hot melt extrusion
Drug delivery Metformin HCl [85], 
terbutaline sulfate [48], 
propranolol [86]
Table 2. Main applications of CS-XG based matrices.
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aqueous solutions at different mixing ratios [90]. SEM images (Figure 6) show the rough sur-
face of CS, whilst XG films produce a smooth surface. Combining the two polymers resulted 
in a pronounced alteration in the surface morphology of the films. The resulting PECs form 
irregular and fibrous surfaces with a porous structure. PECs at a mixing ratio of 1:1 (w/v %) 
showed a dramatic change in the surface structure and it is suggested that they represent the 
maximum interaction between the two polymers.
4.2.2. Initial concentration of XG
Argin-Soysal et al., studied the effect of polymer solution concentration on the formation of 
stable capsules and their subsequent swelling behavior [67]. The initial concentration of the 
XG solution was found to be the determining factor in relation to complexation density, more 
than CS. This is due its high molecular weight and the highly viscous hydrogels it forms when 
in contact with water [91]. The physical cross-linking between XG and CS was complete when 
the concentration of XG was 1.5%, regardless of other experimental conditions. Consequently, 
the degree of swelling was shown to be dictated by the initial aqueous concentration of XG.
4.2.3. pH and initial concentration of CS solutions
Dumitri et al., found that the pH of CS solutions has a moderate effect on the extent of inter-
action between XG and CS [65]. PECs where readily obtained within a wide range of pH 
(3.6–8.0). At lower pH values, the carboxyl groups of XG become protonated (uncharged) 
while the amine groups in CS are fully charged; hence, the interaction between CS and XG is 
CS ∆E
ele
∆E
vdW
∆G
sol
∆G
0% P*, 0% DA −21.290 −14.03 21.890 −13.43
50% P, 0% DA −227.53 −24.47 222.77 −29.22
100% P, 0% DA −419.95 −23.27 412.57 −30.65
0% P, 50% DA −25.080 −21.12 28.460 −17.74
50% P, 50% DA −232.68 −23.96 227.36 −29.28
0% P, 100% DA −25.070 −25.79 30.150 −20.71
Values presented are in kcal/mol.*P represents state of protonation.
Table 3. Binding free energy calculations for XG-CS complexes.
Figure 6. SEM images at magnification power of x2000 of: (a) CS, (b) CS-XG (2:1), (c) CS-XG (1:1), (d) CS-XG (1:2) and (e) 
XG films, from Eftaiha et al. [90].
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impeded and reduced drug retardation occurs. The effect of pH was more pronounced when 
preparing low concentration solutions of CS. A considerable increase in the degree of swelling 
with the pH of solutions at CS concentrations of 0.65–0.7% (w/v) occurs.
4.2.4. Molecular weight (Mw) of CS
The swelling capacity of CS-XG based PECs were found to be influenced by the Mw of CS 
[68]. Lower water retention capacity was achieved by using a higher Mw of CS. The absorp-
tion of water increased noticeably with around 1000% weight gain at lower Mw of CS. The 
increase in water absorption causes the formation of more PEC layers which results in poten-
tially more drug retardation. The aforementioned claim was supported by the slow release 
of diclofenac sodium from low molecular weight CS tablets (13 and 30 kDa) [92]. AlAkayleh 
et al., found that the release rate of terbutaline sulfate from XG-low molecular weight CS 
tablets (viscosity 38 mPa s) was slower than XG-high molecular weight CS (70 mPa s) [48].
4.2.5. DA of CS
The PEC between XG and CS is formed due to the electrostatic attraction between oppositely 
charged groups. Increasing the DA content decreases the number of available free amine 
groups that are readily protonated. In addition, the rigidity of CS chains increased with DA 
owing to strong intramolecular hydrogen bonds dictated by amide groups [93]. As a conse-
quence, the extent of interaction between the polymers is reduced. Release of propranolol HCl 
from an CS-XG matrix was studied as a function of the degree of deacetylation (DDA) of CS 
[86]. Release of drug from the matrix was faster from the acetylated form of CS. This result is 
in accord with the outcomes of the molecular dynamics simulation study (Table 3) [89].
Figure 7. In-vitro release of ambroxol HCl from: (R) reference product, prepared tablets at a P:D of (T1) 1:1, and (T2) 3:1, 
as reported by Al Remawi et al. [94].
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4.2.6. Ionic strength of solution
Adding ionic species to the solution resulted in a large decrease in water uptake of CS-XG 
PECs. Competition takes place between free ions and water molecules for the hydroxyl groups 
of the polymers and reduces the hydration of CS and XG chains. Thus, the degree of swelling 
is lower which, in turn, will have an effect on the drug retardation capability of the system [63].
4.2.7. Concentration of incorporated API
Hydrophilic matrices need to be used at high polymer to drug ratios in order to exert their 
effect in sustaining the release of APIs [27]. Thus, their application is restricted to low strength 
drugs, as addressed by Badwan et al. [71]. Al Remawi et al. studied the effect of polymer to 
drug ratio (P:D) on the release of ambroxol HCl from CS-XG based tablets [94]. The release 
rate of ambroxol was highly dependent on the P:D ratio. Greater retardation of drug release 
was attained at higher polymer ratios (Figure 7).
5. Tablets comprising CS-XG
Oral solid dosage forms remain the most favorable choice to deliver APIs. The main reason is 
that they preserve the physicochemical stability of chemical entities more than liquid forms 
[95]. Additionally, tablets offer advantages for both manufacturers and patients which include 
ease of handling, low production cost, dose precision and self-administration capability [96].
Utilization of CS as an efficient excipient in tablet formulation is gradually increasing. CS 
powder exhibits a high surface area and porosity [93]. It produces tablets with high tensile 
strength that form a network-like structure when examined by microscopy [97]. The aim of 
using a combination of polymers, as tablet excipients, is to enhance compressibility and flow-
ability properties. Furthermore, a polymeric mixture can increase the overall retardation per-
formance of the system. CS-XG based tablets were formulated by compression of one layer 
and multi-layers; they were used solely or with other polymers such as galactomannan, seed 
gum or β-cyclodextrin [48, 85, 86, 98]. Moreover, they were used in immediate release, floating 
mucoadhesive and buccal tablets [99, 100]. According to Badwan et al., combining XG with CS 
has the advantage of improving the mechanical properties of both polymers [93].
5.1. Tablet preparation methods
5.1.1. Direct compression
Direct compression is a technique for formulating tablets which limits the use of solvents, 
temperature and equipment. It is the first choice whenever the API and inactive materials are 
suitable for direct compression and are stable at high pressure [101]. Powders of both active 
and inactive ingredients are mixed homogeneously, then sieved to the desired particle size. 
Finally, the prepared blend is compressed using a tablet press machine at a predetermined 
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pressure [102]. CS-XG based tablets prepared via direct compression, showed a high potential 
towards sustaining the release of terbutaline sulfate and ambroxol [48, 103].
5.1.2. Dry granulation
Dry granulation is utilized to improve compaction properties of ingredients. It can influence 
flowability, stability, content uniformity of the powders and enhance the bioavailability of 
the API. This is attained by increasing the particle size of powder materials via aggregation of 
particles by either roller compaction or slugging and then milling to produce granules with 
the desired size [104].
5.1.3. Wet granulation
Wet granulation of tablet components is usually achieved using water, ethanol or a mixture of 
both. Following drying at an appropriate temperature, granules are mixed with other excipi-
ents if needed, passed through a sieve and finally compressed using a press machine at a 
predefined pressure [105]. Wet granulation is used to produce dust free granules, enhance 
flowability and cohesion. Eftaiha et al., investigated the ability of CS-XG tablets prepared by 
wet granulation using an aqueous solution of XG 1% (w/v) to modify the release of metronida-
zole [87]. The preparation was able to sustain the release of metronidazole, both in-vitro and in-
vivo. A mucoadhesive behavior was observed when applying the tablets on sheep duodenum.
5.1.4. Hot melt extrusion (HME)
In HME the powdered API, functional polymers and any other excipients are blended in a 
mortar and pestle then fed into the hopper of a single or double screw extruder. Fukuda et al., 
prepared CS-XG tablets using HME to study the release of chlorpheniramine maleate [106]. 
The processing temperature was 90°C (zone 1), 95°C (zone 2), 105°C (zone 3) and 110°C (die) 
with a screw speed of 15 rpm. The processing time needed for powders inside the barrel of 
the extruder is usually ~3–4 min. The extruded materials were then manually cut into tablets 
of the desired weights. Chlorpheniramine release from the prepared CS-XG tablets occurred 
in a sustained manner and was independent of the pH and ionic strength of the dissolution 
media. HME offers the advantage of continuous processing and process analytical technology 
(PAT) which enables quality control testing throughout the process [107].
5.2. Mechanism of drug release
Drug release from CS-XG matrices is suggested to be governed by the dissolution rate of the 
drug and the polymers in the media as well as the diffusion of the drug from the matrices and 
erosion of the polymers. The data in Figure 8 illustrates the processes of drug release from a 
tablet composed of CS and XG. When the tablet is first exposed to aqueous media, an insol-
uble gel layer forms on the top surface of the tablet, as a result of polyelectrolyte complex-
ation between the two charged polymers [108]. Water molecules start to penetrate this layer 
towards the matrix owing to the high water uptake capability of XG. [91]. Accordingly, both 
polymers and drug are dissolved and a rubbery hydrated region is formed (white area) [27]. 
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On the other hand, a non-hydrated glassy area is formed at the core of the tablet, where 
no water molecules reach the system (black area) [109]. As time lapses, further penetration 
of water molecules into the tablet occurs resulting in the polymers chains being solvated. 
Consequently, swelling of the matrix occurs [110]. At this stage, water molecules enter 
between the polymer chains, the radius of gyration of the polymers increases and the end-
to-end distance of the polymer backbones also increases [111]. This phenomenon of polymer 
relaxation is referred to as “swelling of the matrix” [91]. As more water molecules pass into 
the matrix, the polymer concentration on the outer surface of the tablet decreases, losing its 
integrity, and starts to dissolve in the medium. This phenomenon is termed “polymer ero-
sion” [112].
The rate of drug release from such a matrix could occur as a function of diffusion of the 
water molecules into the matrix, dissolution of both polymers and drug, polymer relax-
ation and erosion [91, 113]; this depends on the previously mentioned factors (Section 4.2) 
[111, 114].
Figure 8. Schematic representation of the behavior of CS-XG tablets in an aqueous medium.
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6. Conclusions
Controlling the release of active ingredients is one of the fastest growing applications of CS-XG 
based matrices. Various drug delivery systems and newly emerging technologies have been 
developed in order to optimize the foregoing mixture. XG-CS matrices show a high poten-
tial towards controlling the release of a wide range of active biomolecules. The efficiency of 
CS-XG matrices to control the release of drugs can be reinforced by manipulating the physico-
chemical properties of CS and XG and the experimental conditions used. Thus, incorporation/
use of expensive devices and the method of preparation can be kept to a minimum. With 
further optimization and the utilization of newly emerging computational and quality by 
design tools, relatively simple and straightforward CS-XG based matrices can be formulated 
as potentially universal carriers to control the release of APIs.
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